Physician profile
Yogesh Kumar Katechia
NPI 1740265925
$9,423.33
in general payments reported to CMS, 2019-2025
45 companies · $1,233 in 2025
The $1,233 reported for 2025 was more than what 87% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,359 · 2020: $1,201 · 2021: $1,504 · 2022: $1,520 · 2023: $1,204 · 2024: $1,402 · 2025: $1,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,778 · Education: $61.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,777.51 |
| Education | $61.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,692.45 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,375.61 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $673.78 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $589.85 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $581.14 | 2019-2025 | |
| Astellas Pharma US INC | $551.43 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $429.22 | 2019-2025 | |
| Amarin Pharma, INC. | $340.04 | 2019-2023 | |
| Lilly USA, LLC | $303.70 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $276.45 | 2019-2021 | |
| Corcept Therapeutics | $195.32 | 2023-2024 | Korlym |
| Phathom Pharmaceuticals, INC. | $194.45 | 2024-2025 | Voquezna |
| Allergan, INC. | $181.76 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $177.83 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $172.25 | 2021-2023 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yogesh Katechia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.